Navigation Links
Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
Date:5/27/2008

VANCOUVER and SAN DIEGO, May 27 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI, OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, is taking aggressive steps to further reduce expenses to extend its cash runway through the Omigard(TM) Phase III results milestone expected in the second half of 2008 while continuing to focus on advancing the Company's MX-2401 program. Efforts are also underway to raise additional cash which will be required to enable continued key development activities expected to maximize long-term shareholder value and extend the Company's cash position into 2009.

The cost reduction actions include some limited program-related changes, substantial management and board compensation cuts, personnel reductions, and other operational streamlining activities (see "SPECIFIC COST-CUTTING ACTIONS" below).

Jim DeMesa, M.D., President and CEO of MIGENIX stated, "We must preserve our cash during this very difficult financial market for biotech companies. With the significant value-driving milestones we expect during the second half of this year and the first half of next year - along with the potential start of Omigard(TM) related revenues - we must take these actions to extend our cash runway as long as possible while continuing to advance our greatest product opportunities. These actions are expected to achieve both. All of us at MIGENIX are committed to creating value for our shareholders, advancing our pipeline of promising drug candidates and improving lives."

As a result of these initiatives, the following are our potential milestones over the next 12 months:

Omigard(TM) (prevention of catheter-related infections):

--------------------------------------------------------

- Positive Phase III results in H2/08

- NDA submission in H1/09, with the associated milestone payments

- Completion of rest of world partnership(s), with associated up-front

paymen
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MIGENIX First Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
2. MIGENIX to Present Positive Celgosivir Viral Resistance Data at International HCV Meeting
3. MIGENIX Reports First Quarter Fiscal Year 2008 Financial Results
4. MIGENIX to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. MIGENIX Second Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
6. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
7. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
8. MIGENIX releases CEO message #22
9. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
10. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
11. MIGENIX Appoints Pieter Dorsman to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the ... grow moderately through 2023 as the aging population, increasing ... dental biomaterials all spur procedure volumes. Growth will be ... China and India , ... reach for a larger proportion of the population. ...
(Date:12/17/2014)... December 16, 2014 The Activated ... 2013, which is why IBISWorld updated its original industry ... to benefit from an intensified focus on environmental policy. ... new emission standards for power plants and a range ... to IBISWorld Industry Analyst Sarah Kahn, “a range of ...
(Date:12/17/2014)... N.J. (PRWEB) December 17, 2014 ... (Euronext: IPN; ADR: IPSEY), today announced ... (referred to as Somatuline®) was approved by the ... treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult ... advanced or metastatic disease to improve progression-free survival ...
Breaking Biology Technology:iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 2Activated Carbon Manufacturing in the US Industry Market Research Report Has Been Updated from IBISWorld 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... PALO ALTO, Calif. , May 4 "BIO has ... of the biotechnology sector.  It is my goal to build upon these ... fosters the right policy environment for the biobased solutions that our industry ... , , ...
... slips into the sole of your sneaker, but it,s a ... hundreds of times faster ― a communications technology "enabler" that ... the future, currently being created by Dr. Koby Scheuer of ... Scheuer has developed a new plastic-based technology for the nano-photonics ...
... BERLIN and CHICAGO , May ... the most important biotechnology segments in Germany .,With an ... German diagnostics,market, the segment enjoys a compound annual growth ... trends toward personalized,medicine that are correspondingly increasing the market for ...
Cached Biology Technology:Statement from Genencor CEO Tjerk de Ruiter Upon Being Elected as Chair of the Industrial & Environmental Section and Board of Directors of the Biotechnology Industry Association (BIO) 2An optical traffic cop for rapid communication 2BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth 2BIO 2010: German Molecular Diagnostics Segment Posting Double-Digit Growth 3
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... HOUSTON (Jan. 31, 2012) Just the mention ... are often painful and sometimes difficult to remove, and 10 ... the risk of developing kidney stones is exacerbated due to ... that resource limitations and distance from Earth could restrict treatment ...
... Over the past 30 years, numerous studies have linked ... bipolar disorder, schizophrenia, anxiety disorder and dementia. Genetic fragments ... disorders in a range of mammals and birds, have ... study results have been inconsistent. Now, the first ...
... who have Ulcerative Colitis (UC) or Ileal Pouch know ... between flares is crucial to successfully living with the ... drugs, dietary changes and, for many, the addition of ... management of these conditions. Now, Sigma-Tau Pharmaceuticals, Inc., maker ...
Cached Biology News:Twinkle, twinkle kidney stone: With a push you could be gone 2Twinkle, twinkle kidney stone: With a push you could be gone 3Does Borna disease virus cause mental illness? 2Maker of VSL#3 probiotic offers assistance program for ulcerative colitis and ileal pouch patients 2
... Intended for users requiring mass ... AXIMA-LNR linear MALDI TOF Mass spectrometer ... QA/QC applications and for high performance ... oligonucleotide QA/QC, SNP analysis, protein detection, ...
Rat Lung Fibroblasts (RLF) (>500,000 cells)...
... DNA is an ideal small concentrator for ... capable of removing water and organic solvents ... tubes, microplates, vials and round bottom flasks. ... the busy lab. ,The built-in special runs ...
... miVac Duo is suitable for use with ... organic solvents through to water and some ... centrifugal concentrator capable of removing water and ... formats including tubes, microplates, vials and round ...
Biology Products: